Cargando…

Eliminating viral hepatitis C in Belgium: the micro-elimination approach

BACKGROUND: Hepatitis C virus is one of the leading causes of chronic liver disease and liver-related deaths worldwide. The estimated prevalence of chronic hepatitis C viral infection among the general Belgian population was 0.57% (n = 64,000) in 2015. Although Belgium has had a ‘Hepatitis C Plan’ s...

Descripción completa

Detalles Bibliográficos
Autores principales: Busschots, Dana, Toghanian, Samira, Bielen, Rob, Salomonsson, Stina, Koc, Özgür M., Hendrickx, Greet, Jadoul, Michel, Nevens, Frederik, Sokal, Etienne, Brixko, Christian, Peerlinck, Kathelijne, Apers, Ludwig, Robaeys, Geert, Lazarus, Jeffrey V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045456/
https://www.ncbi.nlm.nih.gov/pubmed/32106819
http://dx.doi.org/10.1186/s12879-020-4898-y
_version_ 1783501778819481600
author Busschots, Dana
Toghanian, Samira
Bielen, Rob
Salomonsson, Stina
Koc, Özgür M.
Hendrickx, Greet
Jadoul, Michel
Nevens, Frederik
Sokal, Etienne
Brixko, Christian
Peerlinck, Kathelijne
Apers, Ludwig
Robaeys, Geert
Lazarus, Jeffrey V.
author_facet Busschots, Dana
Toghanian, Samira
Bielen, Rob
Salomonsson, Stina
Koc, Özgür M.
Hendrickx, Greet
Jadoul, Michel
Nevens, Frederik
Sokal, Etienne
Brixko, Christian
Peerlinck, Kathelijne
Apers, Ludwig
Robaeys, Geert
Lazarus, Jeffrey V.
author_sort Busschots, Dana
collection PubMed
description BACKGROUND: Hepatitis C virus is one of the leading causes of chronic liver disease and liver-related deaths worldwide. The estimated prevalence of chronic hepatitis C viral infection among the general Belgian population was 0.57% (n = 64,000) in 2015. Although Belgium has had a ‘Hepatitis C Plan’ since 2014, elimination efforts are unclear. This study employs the best available data and modelling estimates to define the burden of hepatitis C viral infection among key subgroups in Belgium, identify information gaps and propose potential approaches to screening, linkage to care and treatment, and cure. METHODS: We examined the peer-reviewed and grey literature since 2012 for data on the prevalence of hepatitis C viral infection in Belgium in key subgroups identified by national experts and in the literature. Ultimately, this research is primarily based on data provided by the key stakeholders themselves due to a lack of reliable data in the literature. Based on this, we modelled the treatment rates required to reach elimination of hepatitis C in several subgroups. RESULTS: Eleven potential subgroups were identified. There were no data available for two subgroups: generational cohorts and men who have sex with men. In six subgroups, fewer than 3000 people were reported or estimated to have hepatitis C infection. Migrants and people who inject drugs were the most affected subgroups, and children were the least affected subgroup. Only two subgroups are on target to achieve elimination by 2030: patients living with haemophilia and transplant recipients. CONCLUSIONS: Removing Belgian treatment reimbursement restrictions in January 2019 was a big step towards eliminating HCV. In addition, increasing surveillance, including with a national registry, treatment prescription by other health-care providers and availability of treatment in local pharmacies are central to improving the current situation and getting on track to reach the 2030 WHO hepatitis C elimination targets in Belgium.
format Online
Article
Text
id pubmed-7045456
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-70454562020-03-03 Eliminating viral hepatitis C in Belgium: the micro-elimination approach Busschots, Dana Toghanian, Samira Bielen, Rob Salomonsson, Stina Koc, Özgür M. Hendrickx, Greet Jadoul, Michel Nevens, Frederik Sokal, Etienne Brixko, Christian Peerlinck, Kathelijne Apers, Ludwig Robaeys, Geert Lazarus, Jeffrey V. BMC Infect Dis Research Article BACKGROUND: Hepatitis C virus is one of the leading causes of chronic liver disease and liver-related deaths worldwide. The estimated prevalence of chronic hepatitis C viral infection among the general Belgian population was 0.57% (n = 64,000) in 2015. Although Belgium has had a ‘Hepatitis C Plan’ since 2014, elimination efforts are unclear. This study employs the best available data and modelling estimates to define the burden of hepatitis C viral infection among key subgroups in Belgium, identify information gaps and propose potential approaches to screening, linkage to care and treatment, and cure. METHODS: We examined the peer-reviewed and grey literature since 2012 for data on the prevalence of hepatitis C viral infection in Belgium in key subgroups identified by national experts and in the literature. Ultimately, this research is primarily based on data provided by the key stakeholders themselves due to a lack of reliable data in the literature. Based on this, we modelled the treatment rates required to reach elimination of hepatitis C in several subgroups. RESULTS: Eleven potential subgroups were identified. There were no data available for two subgroups: generational cohorts and men who have sex with men. In six subgroups, fewer than 3000 people were reported or estimated to have hepatitis C infection. Migrants and people who inject drugs were the most affected subgroups, and children were the least affected subgroup. Only two subgroups are on target to achieve elimination by 2030: patients living with haemophilia and transplant recipients. CONCLUSIONS: Removing Belgian treatment reimbursement restrictions in January 2019 was a big step towards eliminating HCV. In addition, increasing surveillance, including with a national registry, treatment prescription by other health-care providers and availability of treatment in local pharmacies are central to improving the current situation and getting on track to reach the 2030 WHO hepatitis C elimination targets in Belgium. BioMed Central 2020-02-27 /pmc/articles/PMC7045456/ /pubmed/32106819 http://dx.doi.org/10.1186/s12879-020-4898-y Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Busschots, Dana
Toghanian, Samira
Bielen, Rob
Salomonsson, Stina
Koc, Özgür M.
Hendrickx, Greet
Jadoul, Michel
Nevens, Frederik
Sokal, Etienne
Brixko, Christian
Peerlinck, Kathelijne
Apers, Ludwig
Robaeys, Geert
Lazarus, Jeffrey V.
Eliminating viral hepatitis C in Belgium: the micro-elimination approach
title Eliminating viral hepatitis C in Belgium: the micro-elimination approach
title_full Eliminating viral hepatitis C in Belgium: the micro-elimination approach
title_fullStr Eliminating viral hepatitis C in Belgium: the micro-elimination approach
title_full_unstemmed Eliminating viral hepatitis C in Belgium: the micro-elimination approach
title_short Eliminating viral hepatitis C in Belgium: the micro-elimination approach
title_sort eliminating viral hepatitis c in belgium: the micro-elimination approach
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045456/
https://www.ncbi.nlm.nih.gov/pubmed/32106819
http://dx.doi.org/10.1186/s12879-020-4898-y
work_keys_str_mv AT busschotsdana eliminatingviralhepatitiscinbelgiumthemicroeliminationapproach
AT toghaniansamira eliminatingviralhepatitiscinbelgiumthemicroeliminationapproach
AT bielenrob eliminatingviralhepatitiscinbelgiumthemicroeliminationapproach
AT salomonssonstina eliminatingviralhepatitiscinbelgiumthemicroeliminationapproach
AT kocozgurm eliminatingviralhepatitiscinbelgiumthemicroeliminationapproach
AT hendrickxgreet eliminatingviralhepatitiscinbelgiumthemicroeliminationapproach
AT jadoulmichel eliminatingviralhepatitiscinbelgiumthemicroeliminationapproach
AT nevensfrederik eliminatingviralhepatitiscinbelgiumthemicroeliminationapproach
AT sokaletienne eliminatingviralhepatitiscinbelgiumthemicroeliminationapproach
AT brixkochristian eliminatingviralhepatitiscinbelgiumthemicroeliminationapproach
AT peerlinckkathelijne eliminatingviralhepatitiscinbelgiumthemicroeliminationapproach
AT apersludwig eliminatingviralhepatitiscinbelgiumthemicroeliminationapproach
AT robaeysgeert eliminatingviralhepatitiscinbelgiumthemicroeliminationapproach
AT lazarusjeffreyv eliminatingviralhepatitiscinbelgiumthemicroeliminationapproach